Limitations, agreements, and source contact

Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM · Source last updated 2022-12-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

On 04 November 2021, the study was terminated early during Phase 2a.

point Of Contact

email

trials@oncopeptides.com

organization

Oncopeptides AB

phone

+46 8 615 20 40

title

VP Chief Operating Officer

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice